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Abstract
Mycobacterium tuberculosis m-RNA quantitation in sputum of pulmonary tuberculosis patients before starting supervised treatment was
evaluated as a surrogate for response. Sputum specimens were collected from 50 patients (DOTS category II treatment; 303 specimens,
day 0 to fourth month) and 16 controls (non-tubercular lung disorders). Microscopy, reverse-transcriptase PCR and DNA-PCR were
compared with culture using the BACTEC 460 system. TaqMan real-time RT-PCR quantitated the mRNA levels. RT-PCR (sensitivity, 10
organisms/mL) and culture results were concordant. mRNA declined with time and correlated with culture clearance. Thirty-nine (78%)
patients were smear, culture and RT-PCR negative at 2 months of treatment. Day 0 mRNA levels had statistically signiﬁcant correlation
with time to culture conversion and drug resistance (p 0.041). Of seven patients with sensitive isolates but high m-RNA levels, four pre-
sented with re-infection/mixed infection later, while three presented with relapse (ninth to twentieth month). The control group speci-
mens were negative for the above tests. M. tuberculosis mRNA in the sputum is a useful prognostic marker and its quantitation an early
and reliable indicator for monitoring response, prediction of culture conversion, drug resistance, re-infection and relapse. mRNA quanti-
tation may prove to be of great value for evaluating the response to new drugs under trial.
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Introduction
In 2010, there were 8.8 million (range, 8.5–9.2 million) incident
cases of TB, 1.1 million (range, 0.9–1.2 million) deaths from TB
among HIV-negative people and an additional 0.35 million
(range, 0.32–0.39 million) deaths from HIV-associated TB [1].
The escalating problems of drug resistance and co-infection
with HIV are making control of the disease difﬁcult.
The traditional mainstay for the diagnosis of TB is the identi-
ﬁcation of bacilli on direct microscopy combined with culture
and antibiotic sensitivity despite the diagnostic limitations. The
nucleic acid ampliﬁcation tests for detection of mycobacterial
DNA/rRNA have aided rapid diagnosis of TB [2,3] and offered
enhanced sensitivity but have proven incongruous for detecting
viability of bacteria and response to chemotherapy [4,5].
Sputum conversion at 1–2 months after initiation of treat-
ment and sterilization of active lesions has long been used as
a surrogate for assessing response to anti-tubercular therapy
[6]. New drug validation trials require recruitment of large
numbers of patients, who must be followed closely (usually
for 12–24 months after treatment) in order to detect trial
endpoints (failure and relapse) reliably; such trials are thus
lengthy and expensive. Development of a surrogate marker
for drug trials would pave the way for assessing patient prog-
nosis, as well as early drug validations.
Bacterial mRNA (half-life of 3–5 min) [7] is more vulnera-
ble to destruction than rRNA or genomic DNA. In this
study, mRNA-based RT-PCR was used as a marker of Myco-
bacterium tuberculosis viability in sputum specimens collected
from DOTS category II (relapse, treatment failure or default
cases) TB patients receiving an optimal drug regimen. These
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patients need careful monitoring, essentially because a sub-
stantial proportion of them may be harbouring resistant
organisms. A delayed diagnosis of resistance, in the absence
of an effective surveillance network, would only enhance
transmission in the community.
Materials and Methods
See the web only/supplementary material for an extended
version of METHODS.
Study specimens
The study was conducted in DOTS category II pulmonary
TB patients, enrolled at the All India Institute of Medical Sci-
ences, New Delhi. Between May 2005 and January 2008, 303
sputum specimens were collected from 50 patients at the
following time-points: day 0, second week, fourth week, sixth
week, eighth week, and the third month, followed by a
monthly sputum specimen till 26 months. After collecting the
day 0 specimen, patients were put on treatment. Patients
diagnosed with MDR-TB (resistance to INH and RIF, with or
without resistance to other drugs) were sent to the Rajan
Babu Institute of Pulmonary Medicine and Tuberculosis
(RBIPMT), Delhi, for hospitalization and further work-up.
The additional details of the treatment regimen are given in
the online data supplement. Each subject gave informed con-
sent by signing a statement in the local language. The study
was approved by the Institutional Ethics Committee.
Smear microscopy, culture, sensitivity, RT-PCR, DNA-PCR
and qRT-PCR were performed on specimens collected from
day 0 to the third month. For the specimens collected after
the third month, smear microscopy and culture were done.
Patient control group
Sputum specimens were collected from 16 patients with
other lung disorders (e.g. chronic bronchitis, lung cancer).
These specimens were processed identically to those
obtained from the patients in the study group in order to
assess the speciﬁcity of assays used in the study.
RNA and DNA isolation
RNA isolation. RNA was extracted as per the protocol published
by Jou et al. [8] with certain modiﬁcations. To rule out any
contaminating DNA, the RNA was treated with RNase – free
DNase I (New England Biolabs Inc., Ipswich, MA, USA). The A260/
A280 ratio was checked to test the purity of extracted RNA.
DNA isolation. Two hundred microlitres of lysis buffer was
added to an equal amount of the concentrated sputum
sediment. The sample was lysed at 60C for 2 h and 95C
for 15 min. The DNA was extracted using the QIAamp
DNA extraction kit (Qiagen, Hilden, Germany) as per the
manufacturer’s instructions.
RT-PCR
cDNA was synthesized in a 25-lL reaction mixture using
the High Capacity cDNA Archive kit (Applied Biosystems,
Foster city, CA, USA) as per the protocol described.
cDNA was stored at )20C until PCR ampliﬁcation. Fol-
lowing reverse transcription, ampliﬁcation was performed in
a nested manner using primers described by NT Jou et al.
[8]. The additional details of PCR ampliﬁcation are provided
in the online data supplement.
qRT-PCR
Enumeration of Ag85B mRNA was carried out using real-time
PCR (qRT-PCR). Real-time PCR assay was carried out in a 25-
lL reaction with one-step RT-PCR master mix using the ABI
Prism 7000 Sequence Detector System (Perkin Elmer Corp./
Applied Biosystems, Boston, MA, USA). The sequence of pri-
mer and probe and additional details of qRT-PCR ampliﬁcation
are provided in the online data supplement.
DNA-PCR
The mpt64 gene was used as a target for DNA-PCR. A 240-
bp region of the mpt64 gene of M. tuberculosis was ampliﬁed
following the procedure described previously [9].
Spoligotyping
Spoligotyping was performed to characterize relapsed cul-
tures using the Isogen Bioscience kit (Maarsen, the Nether-
lands) according to the manufacturer’s instructions.
Results
Demographic characteristics of the patients
A table showing the baseline characteristics of the patients is
provided in the online data supplement (Table S1). Twenty-
ﬁve (71.4%) men had cavitary disease while only 10/15
(66.6%) of the women had cavitary disease.
Sputum bacterial load
All the patients except one had positive sputum smears on
day 0 (enrolled based on culture results). Fourteen patients
had 1+ sputum smears, eight had 2+ sputum smears, 12 had
3+ sputum smears, and 15 had scanty [10]. Enumeration of
AFB by microscopy showed a relatively rapid decline
between day 0 and the second week of treatment (Fig. 1).
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Culture
Almost 50% (24/50) of the cultures (BACTEC) converted to
negative by 4 weeks of treatment and 78% (39/50) converted
by 2 months of treatment (Fig. 1).
Drug-sensitivity testing
Drug-sensitivity testing results showed that 37 patients (74%)
harboured drug-sensitive strains and 13 (26%) harboured
resistant strains of M. tuberculosis. Of 13 drug-resistant
strains, seven were MDR. Table S2, showing this distribution,
is provided in the online data supplement.
RT-PCR
Day 0 specimens of 47 (94%) patients were positive for RT-
PCR while 45 were positive by culture. RT-PCR showed high
concordance with the culture results at all time-points
(Fig. 1), with the exception of three sputum specimens
(two 0–day specimens and one 6-week specimen) that had
positive RT-PCR but negative BACTEC culture and two spu-
tum specimens that had negative RT-PCR (one 6-week speci-
men and one 4-week specimen) and positive BACTEC
culture.
qRT-PCR
Ag85B mRNA in sputum specimens was quantitated using
real-time RT PCR assay on day 0, day 30 and day 60. If the
day-60 specimen showed any signiﬁcant amount of mRNA,
the next sample was also quantitated. All values were log
transformed to base 10. There was a marked difference in
mRNA levels when patients were classiﬁed according to
drug-sensitivity patterns. Baseline 85B mRNA levels proved
to be potentially indicative of M. tuberculosis drug susceptibil-
ity. The levels of 85B mRNA for individual patient specimens
changed with treatment (Fig. 2).
DNA-PCR
All 50 sputum specimens were positive for DNA-PCR on
day 0. All the specimens positive by smear microscopy were
positive by DNA-PCR; even the specimens that were culture
negative but microscopy positive were positive by DNA-
PCR. Overall, DNA-PCR continued to be positive even
when smear, culture and RT-PCR converted to negative
(Fig. 1). However, the number of DNA PCR-positive patients
fell with time, more steadily for the sensitive patient group
than for the group with resistant patients, while the slow
responders and the relapse patients continued to have a
positive DNA PCR (Fig. 2a,b).
Statistical analysis
Kaplan-Meier survival analysis was performed for smear and
culture conversion. Smear and culture conversion took place
at 4 weeks for 50% of the patients (including patients with
both drug-sensitive and drug-resistant proﬁles) and the med-
ian time for culture conversion was 6 weeks.
Pearson’s chi-square test was applied to study the correla-
tion between day 0 RT-PCR results and demographic charac-
teristics of the patients. A signiﬁcant correlation was
observed with age (p 0.014) (i.e. RT-PCR was more often
found to be positive in the younger age group, 15–45 years).
Non-parametric tests were applied to study correlation
between qRT-PCR values (number of 85B mRNA molecules/
mL of specimen) and parameters such as smear and culture
conversion (Fig. 3a,b).
Slow responders
Patients were designated as slow responders depending on
the BACTEC culture status at week 8 after start of treat-
ment [11]. Of the 50 enrolled patients, 11 (22%) were cul-
ture and RT-PCR positive at week 8 (six patients from the
drug-sensitive group and ﬁve patients from the drug-resistant
group) (Figs 2 and 4).
Relapse/re-infection
A patient who was previously declared cured or ‘treatment
completed’ and is again diagnosed with bacteriologically posi-
tive sputum smear or culture was designated as a relapse
case [1]. Nine patients (seven drug-sensitive and two drug-
resistant) had relapse of tubercular infection after the com-
pletion of chemotherapy (Figs 2 and 5).
BACTEC culture and sensitivity testing for sputum speci-
men relapse showed that four (4/7; 57.1%) of the relapsed
cultures from drug-sensitive group patients were now drug-
resistant with a different spoligotype pattern. This clearly sig-
nals re-infection/mixed infection (Table 1). The two (2/2)
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FIG. 1. Number of patients positive for smear microscopy, culture
(BACTEC and LJ), RT-PCR and DNA-PCR on day 0, and at week 2,
week 4, week 8 and week 12.
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FIG. 2. (a) Scatter plot diagram for evaluation of Ag85B mRNA levels
in the day 0, week 4 and week 8 sputum specimen of DOTS category
II pulmonary tuberculosis patients with drug-sensitive and drug-resistant
proﬁles. Each circle represents molecules of mRNA/mL of sputum
(log10) for individual patients. The highest amount of mRNA was
found in day 0 specimens, which decreased substantially in the fourth
week specimens and eighth week specimens. Mean number of mole-
cules of mRNA/mL of sputum (log) in day 0 sputum specimens was
4.28, in week 4 specimens was 0.74 and in week 8 specimens was 0.12.
For drug-sensitive and drug-resistant patient groups, the mean number
of 85B mRNA molecules/mL of sputum (log) on day 0 was 3.99 (SD
1.53) and 5.09 (SD 1.82), respectively. In the fourth week, the mean
value was 0.62 for drug-sensitive patients and 1.10 for drug-resistant
patients. By the eighth week, there was virtually no detectable mRNA
in patients with drug-sensitive proﬁles (mean 0.17) though patients
with drug-resistant proﬁles showed some measurable mRNA (mean
0.44). Nine patients, including seven patients harbouring drug-sensitive
isolates, relapsed in the period between 8 and 20 months, and two
patients with drug-resistant isolates relapsed at 8 and 9 months,
respectively. The m-RNA levels in the baseline sputum specimens of
the patients with drug-resistant isolates (mean value 5.09) were signiﬁ-
cantly higher than for the sensitive group patients (mean value 3.99).
Eleven patients were slow responders, of whom nine had high levels of
85B mRNA at baseline (mean 5.87) and fourth week specimens (mean
1.73), though one patient from each group had lower levels of 85B
mRNA. p-values have been calculated by Mann–Whitney U-test,
except for the relapse sensitive and resistant group, where the
unpaired t-test was used. Only signiﬁcant p-values (p <0.05) are pre-
sented here. The grey bar is the median and vertical lines are the inter-
quartiles. (b) DNA-PCR in the day 0, week 4 and week 8 sputum
specimens of DOTS category II pulmonary tuberculosis patients with
drug-sensitive and drug-resistant proﬁles. Each blue bar represents the
number of patient samples with positive PCR and each red bar repre-
sents the number of patient samples with negative PCR. The highest
positivity (100%) was found in day 0 specimens, which decreased sub-
stantially in the fourth week specimens and eighth week specimens. In
the drug-sensitive group, fourth week specimens, % positivity was 64.8
and in eighth week specimens 29.7. For drug-resistant patient groups,
the % positivity in the fourth week was 61.5 and by the eighth week, %
positivity was 46.1. Nine patients, including seven patients harbouring
drug-sensitive isolates, relapsed in the period between 8 and
20 months, and two patients with drug-resistant isolates relapsed at 8
and 9 months, respectively. The DNA turned positive when the
patient relapsed. In the slow responder group, the DNA PCR was
positive; in all nine patients till 8 weeks, except one where it was nega-
tive in the fourth week. (c) The RNA and DNA decay curves have the
same slope.
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drug-resistant patients with relapse had MDR isolates both
before and after relapse with the same spoligotype (Table 2).
Subject control group
All the specimens collected from control group subjects
were negative for M. tuberculosis by smear microscopy, BAC-
TEC culture and DNA-PCR. No Ag85B mRNA was detected
by qRT-PCR in any of these samples.
Discussion
Early detection and treatment are vital for the containment
of tuberculosis infection and prevention of MDR and XDR-
TB. Timely assessment of the treatment being administered
in patients with the possibility of drug resistance and
relapse of infection is important. Bacilli in patients on
(b)
(a)
FIG. 3. (a) Correlation between smear grading and culture conversion.
Patients with higher real-time RT-PCR values (number of 85B mRNA
molecules/mL of specimen) had higher smear grading (scanty (p 0.0473),
1+ (p 0.0146), 2+ (p 0.0048), 3+ (p 0.0005)). Sputum grading in day 0
sputum specimens showed signiﬁcant correlation with time for culture
conversion in both sensitive and resistant patients (i.e. patients with
higher grading values converted later). Sputum grading has been plotted
in increasing order. The blue curve represents the smear status. Scanty
positives are represented by 0.5, 1+ by 1, 2+ by 2, and 3+ by 3. Note:
Data on culture conversion was not available from ﬁve patients, hence
not analysed in the graph. (b) Correlation between qRT-PCR values
(number of 85B mRNA molecules/mL of specimen) and culture conver-
sion. Levels of 85B mRNA in day 0 sputum specimens showed signiﬁcant
correlation with time for culture conversion in both sensitive (p 0.027)
and resistant patients (p 0.007) (i.e. patients with higher day 0 real-time
RT-PCR values converted later). Comparing the two ﬁgures, the m-
RNA (molecules/mL) correlated consistently with culture conversion
and can hence be used as a useful predictor of culture conversion (m-
RNA values have been plotted in increasing order). Note: Data on cul-
ture conversion from ﬁve patients and mRNA levels from one patient
was not available, hence not analysed in the graph.
(a)
(b)
FIG. 4. Eleven patients were slow responders, of whom nine had
high levels of 85B mRNA at baseline (mean 5.87) and fourth week
specimens (mean 1.73), though one patient from each group had
lower levels of 85B mRNA. (a) Five patients from the sensitive
group. (b) Four patients from the resistant group.
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treatment become non-cultivable [12] while DNA/rRNA
targets are incapable of detecting viability. mRNA, because
of its short half-life, can be used to project viability of the
organism, therapeutic efﬁcacy and/or susceptibility to anti-
bacterial agents. The present study was designed to quanti-
tate Ag85B mRNA by real-time PCR [7,12–14], in DOTS
category II patients in a controlled setting, as a marker of
viability and validate its utility in predicting response to che-
motherapy and drug resistance/relapse in patients on treat-
ment.
Several surrogate markers have been used as indicative of
response to treatment in clinical trials. The best studied is
sputum culture conversion at 2 months after start of therapy
[10], though its poor positive predictive value for relapse
(18%) limits its potential role in the management of individual
patients, and its poor sensitivity (50%) indicates the inability
to predict half of all relapses. The validation of new surro-
gate markers that reliably predict relapse and resistance can
contribute signiﬁcantly to tuberculosis control and new drug
discovery.
In our study, smears converted for 50% of patients at
4 weeks of treatment and by the end of 2 months of treat-
ment 78% (39/50) of the patients were both smear and cul-
ture negative (75–85% convert at 2 months [15–18]). DNA-
PCR from the sputum specimens continued to be positive
even when the smear, culture and RT-PCR turned negative,
possibly due to dead bacterial DNA or intact dormant or
dead bacilli from the infection site [14,20,21]. However, the
% positivity of patient samples followed over 0–8 weeks,
showed a steady downward slope in the sensitive group,
steeper when compared with the resistant group, while the
patients in the relapsed and slow responder groups contin-
ued to have a positive DNA PCR, with an odd exception;
hence instead of a slope there was a plateau (Fig. 2a,b). The
slopes clearly differed between responders and non-respond-
ers. Hence a rapid decline in DNA concentration correlates
with better outcome as well. The RNA and DNA decay
curves have about the same slope.
Ag85B mRNA RT-PCR showed high concordance (98.4%)
with BACTEC culture results, indicating successful use of
mRNA as a marker of mycobacterial viability, with discordance
TABLE 1. Time of relapse, anti-tubercular drug susceptibility and spoligopatterns of re-infection/mixed infection isolates
Patient
ID
Time of
relapse
Anti-tubercular
drug susceptibility
(RESI) Spoligopattern
Spoligo
type
5 15th M 0 week – SSSS ST*26
15th M – SSSR ST1
10 15th M 0 week – SSSS ST50
15th M–- RSRR ST42
14 8th M 0 week – SSSS ST42
8th M – RSSS U
46 15th M 0 week – SSSS U
15th M – RSSS U
ST, spoligotype pattern; U, unique spoligotype; R, rifampicin; E, ethambutol; S, streptomycin; I-INH; M, month.
(a)
(b)
FIG. 5. Seven patients harbouring drug-sensitive isolates relapsed in
the period between 8 and 20 months (a), while two patients with
drug-resistant isolates relapsed at 8 and 9 months, respectively (b).
It was observed that mRNA levels in the baseline sputum speci-
mens of the patients with drug-sensitive isolates were signiﬁcantly
higher than the mean value for the sensitive group patients (mean
3.99).
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in only ﬁve samples (possibly due to higher sensitivity of RT-
PCR in three and presence of inhibitors for RT-PCR in two).
RT-PCR results obtained on day 0 specimens showed a
signiﬁcant correlation with age (p 0.014) (higher in the youn-
ger age group, 15–45 years). Poorer immune response in the
older age group, leading to infrequent cavity formations and
hence pauci-bacillary disease, similar to the setting observed
in HIV patients, may explain such a correlation.
Higher mRNA levels on day 0 were associated with drug
resistance. The difference in day 0 mRNA levels in sputum
specimens with drug-sensitive and drug-resistant strains was
found to be statistically signiﬁcant (p 0.041). Quantitative
measurement of 85B mRNA on day 0 could hence be used
as an indication of drug-resistance pattern. Available com-
mercial assays have limitations, such as lack of knowledge of
all the mutations associated with development of resistance.
Qualitative RT-PCR assay for M. tuberculosis 85B mRNA for
the determination of susceptibility to INH has been used
previously [7]; however, it required prolonged incubation
(similar to the proportion method in liquid culture). In con-
trast, qRT-PCR assay values on day 0 helped us to measure
mRNA levels as a surrogate for drug resistance.
Sputum specimens of 11 patients (22%) were culture and
RT-PCR positive at the eighth week of treatment. Nine of
these 11 patients had high levels of 85B mRNA in day 0
(mean 5.87) and week 4 specimens (mean 1.73). This obser-
vation was found to be statistically signiﬁcant for both patient
groups with drug-sensitive (p 0.027) and drug-resistant
(p 0.007) proﬁles. Parameters such as high levels of WBC,
neutrophils and monocytes, expression of IL-4 (interleukin-
4), raised immune markers in blood, no improvement in
chest X-ray, and positive PCR and culture have been
reported in slow responders [19,22,23]; however, no signiﬁ-
cant differences in chest X-ray ﬁndings, extent of disease and
presence, number or size of cavities, or other parameters,
were noticed between slow responders and other patients
in our study.
The baseline levels of mRNA molecules predicted the
chances of relapse in >80% patients. Hence the quantitative
RT PCR appears to be an efﬁcient surrogate for predicting
relapse as well as resistance. Kruuner et al. [24] showed that
75% of all relapses were detected by 6 months (range 65–
84%) and 89% were detected after 1 year of follow-up
(range 75–100%). An early prediction of relapse can guide
modiﬁcation of the treatment protocols.
Recurrence of tubercular infection has long been believed
to be due to reactivation of the strain that caused the initial
infection. The development of DNA ﬁngerprinting techniques
has provided evidence for mixed/multiple infection in a single
host before, during or after successful treatment [25,26].
Seven patients in the drug-sensitive and two patients in the
drug-resistant group presented with relapse of infection after
treatment completion. Drug-susceptibility testing and strain-
typing by spoligotyping performed on the relapsed cultures
revealed the presence of drug-resistant isolates in 57.1% of
the sensitive group patients.
Higher m-RNA values on day 0 and in the fourth week
signalled drug resistance and relapse. Day 0 levels of mRNA
molecules predicted the chances of relapse in >80% of
patients. We propose different treatment regimens for sam-
ples with higher m-RNA values (higher smear grading).
Higher day 0 qRT-PCR values (and higher smear grading)
were consistently seen to be associated with relapse/resistance
and delayed culture conversion. The study has brought forth
the proposal that modiﬁed treatment protocols for patients
with higher bacillary loads may help in efﬁcient treatment and
control. Rapid and accurate identiﬁcation of the viability of
M. tuberculosis is essential for breaking chains of transmission,
treating drug resistance optimally, and understanding the mech-
anisms underlying pathogenesis, drug resistance and latency/
dormancy. The novel observation of change of the spoligotype
during treatment has posed several new questions. Mixed infec-
tion/re-infection can explain the issue, but nevertheless raise
questions regarding pathogenesis of the disease and are a cause
TABLE 2. Time of relapse, anti-tubercular drug susceptibility and spoligopatterns of relapsed isolates
Patient
ID
Time of
relapse
Anti-tubercular
drug susceptibility
(RESI¤) Spoligopattern
Spoligo
type
13 20th M 0 week – SSSS ST*1
20th M – SSSS ST2
16 9th M 0 week – SSSS ST26
8th M – SSSS ST26
20 12th M 0 week – SSSS ST26
12M – SSSS ST26
42 9th M 0 week – RSSR U
15th M – RSSR U
49 8th M 0 week – RSSR ST203
15th M –RRRR ST203
ST, spoligotype pattern; U, unique spoligotype; R, rifampicin; E, ethambutol; S, streptomycin, I-Isoniazid; M, month.
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of concern. A marker that can predict drug resistance or
relapse of infection and help to assess the response to standard
and new anti-tuberculosis drugs accurately within a few days
after start of chemotherapy would be of help in managing treat-
ment of individual patients, thereby allowing treatment to be
individualized according to the relapse risk [27]. It would also
permit clinical resources to be focused on the patients antici-
pated to have poor outcomes, either by intensiﬁcation or pro-
longation of treatment, or by enhanced post-treatment
surveillance [28]. mRNA quantitation through the course of
treatment may reﬂect the response to chemotherapy and
hence serve as an early surrogate for new drug validation trials.
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